[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0721505T4 - Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse - Google Patents

Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse

Info

Publication number
DK0721505T4
DK0721505T4 DK95930434T DK95930434T DK0721505T4 DK 0721505 T4 DK0721505 T4 DK 0721505T4 DK 95930434 T DK95930434 T DK 95930434T DK 95930434 T DK95930434 T DK 95930434T DK 0721505 T4 DK0721505 T4 DK 0721505T4
Authority
DK
Denmark
Prior art keywords
diagnostic
envelope proteins
therapeutic use
virus envelope
purified hepatitis
Prior art date
Application number
DK95930434T
Other languages
English (en)
Other versions
DK0721505T3 (da
Inventor
Fons Bosman
Geert Maertens
Martynoff Guy De
Marie-Ange Buyse
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8218662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0721505(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Application granted granted Critical
Publication of DK0721505T3 publication Critical patent/DK0721505T3/da
Publication of DK0721505T4 publication Critical patent/DK0721505T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109—Hepatitis C virus; Hepatitis G virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24241—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/911—Microorganisms using fungi
    • Y10S435/913—Aspergillus
    • Y10S435/915—Aspergillus flavus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK95930434T 1994-07-29 1995-07-31 Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse DK0721505T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94870132 1994-07-29
PCT/EP1995/003031 WO1996004385A2 (en) 1994-07-29 1995-07-31 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Publications (2)

Publication Number Publication Date
DK0721505T3 DK0721505T3 (da) 2002-08-19
DK0721505T4 true DK0721505T4 (da) 2006-08-14

Family

ID=8218662

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95930434T DK0721505T4 (da) 1994-07-29 1995-07-31 Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse

Country Status (13)

Country Link
US (7) US6150134A (da)
EP (3) EP0721505B2 (da)
JP (3) JPH09503396A (da)
AT (1) ATE217345T1 (da)
BR (1) BR9506059A (da)
CA (1) CA2172273A1 (da)
DE (2) DE69526636T3 (da)
DK (1) DK0721505T4 (da)
ES (1) ES2174957T5 (da)
HK (1) HK1049022A1 (da)
PT (1) PT721505E (da)
SG (1) SG71728A1 (da)
WO (1) WO1996004385A2 (da)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG71728A1 (en) 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
US20040185061A1 (en) * 1994-07-29 2004-09-23 Innogenetics N.V. Redox reversible HCV proteins with native-like conformation
ATE417109T1 (de) 1994-07-29 2008-12-15 Novartis Vaccines & Diagnostic Hepatitis c e2 verkuerzte polypeptid sowie verfahen zu seiner herstellung
CA2288374A1 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
ES2297889T3 (es) 1997-07-14 2008-05-01 Bolder Biotechnology, Inc. Derivados de hormona de crecimiento y proteinas relacionadas.
US20080076706A1 (en) 1997-07-14 2008-03-27 Bolder Biotechnology, Inc. Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en) 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
EP1028742B1 (en) * 1997-11-06 2006-12-27 Innogenetics N.V. Apo b, annexin v and tubulin : medical, diagnostic and purification uses for hcv
AU752131C (en) * 1997-11-06 2003-12-04 Innogenetics N.V. Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes
EP0947525A1 (en) 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue
AU751362B2 (en) * 1998-04-17 2002-08-15 Innogenetics N.V. Improved immunodiagnostic assays using reducing agents
TR200003843T2 (tr) 1998-06-24 2001-06-21 Innogenetics N.V. HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
US7108855B2 (en) * 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
WO2000005266A1 (en) * 1998-07-21 2000-02-03 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Anti hepatitis c virus antibody and uses thereof
US20030180284A1 (en) * 1998-11-05 2003-09-25 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
US8288126B2 (en) 1999-01-14 2012-10-16 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
JP2002534119A (ja) * 1999-01-14 2002-10-15 ボルダー バイオテクノロジー， インコーポレイテッド 自由システイン残基を有するタンパク質の生産方法
US7009044B1 (en) * 1999-06-04 2006-03-07 The United States Of America As Represented By The Department Of Health And Human Services HCV/BVDV chimeric genomes and uses thereof
MXPA02004052A (es) * 1999-10-27 2002-11-07 Innogenetics Nv Proteinas de hcv reversibles por redox con conformacion pseudo-nativa.
NZ518999A (en) * 1999-11-19 2002-12-20 Csl Ltd Vaccine compositions
US6740323B1 (en) * 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
JP2002030098A (ja) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
EP1354064A2 (en) * 2000-12-01 2003-10-22 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002238502B2 (en) * 2001-01-11 2007-09-06 Genimmune N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
DE60231475D1 (de) * 2001-01-12 2009-04-23 Molecules Of Man Ab Materialien und methoden zur behandlung von hepatitis c
BR0209034A (pt) * 2001-04-24 2005-02-01 Innogenetics Nv Proteìnas de envoltório de hcv glicosiladas no núcleo
AU2002322358B2 (en) * 2001-06-29 2009-06-18 Novartis Vaccines And Diagnostics, Inc. HCV E1E2 vaccine compositions
US20040126395A1 (en) * 2001-12-18 2004-07-01 Geert Maertens Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
ATE397619T1 (de) 2003-01-31 2008-06-15 Organon Nv Verfahren zur proteinisolierung unteranoxischen bedingungen
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
US7788040B2 (en) * 2003-12-19 2010-08-31 Siemens Medical Solutions Usa, Inc. System for managing healthcare data including genomic and other patient specific information
JP4885476B2 (ja) * 2004-05-21 2012-02-29 株式会社日本触媒 タンパク質及び／又はペプチドの細胞内導入方法
SG156652A1 (en) 2004-10-18 2009-11-26 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis c infection
US20060292647A1 (en) * 2004-12-03 2006-12-28 Green Lawrence R Reflex supplemental testing - A rapid, efficient and highly accurate method to identify subjects with an infection, disease or other condition
US20080124738A1 (en) * 2005-03-01 2008-05-29 Pritest, Inc Compositions and methods of testing for tuberculosis and mycobacterium infection
JP2008151505A (ja) * 2005-04-05 2008-07-03 Biomarker Science:Kk インターフェロン療法の有効性判定方法及び判定用キット
WO2008025067A1 (en) * 2006-08-30 2008-03-06 Hepgenics Pty Ltd Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same
EP2201023A2 (en) * 2007-09-14 2010-06-30 GENimmune N.V. Affinity tag
US20110091495A1 (en) * 2008-04-22 2011-04-21 Rutgers, The State University Of New Jersey Hcv e2 construct compositions and methods
US9758794B2 (en) 2008-04-22 2017-09-12 Rutgers, The State University Of New Jersey HCV E2 construct compositions and methods
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
US20100104555A1 (en) * 2008-10-24 2010-04-29 The Scripps Research Institute HCV neutralizing epitopes
CN107375919B (zh) 2009-03-27 2022-07-29 台湾地区“中央研究院” 抗病毒免疫的方法和组合物
US10080799B2 (en) * 2010-02-12 2018-09-25 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions related to glycoprotein-immunoglobulin fusions
WO2011147863A1 (en) 2010-05-25 2011-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of anti-envelope antibodies and anti-receptor antibodies for the treatment and prevention of hcv infection
US9512184B2 (en) 2011-05-20 2016-12-06 Emory University Hepatitis C virus particles, vaccines, compositions and methods related thereto
TW201346040A (zh) * 2012-03-30 2013-11-16 Tanaka Precious Metal Ind 流行性感冒ａ型病毒檢驗用套組
CN104812376A (zh) 2012-09-27 2015-07-29 Msd消费保健品公司 起泡的护肤制剂
US20170242010A1 (en) * 2014-02-11 2017-08-24 The Regents Of The University Of California Combo-Hepatitis Antigen Assays and Kits for Detection of Active Hepatitis Virus Infections
SG11201806622PA (en) 2016-02-05 2018-09-27 Univ Texas Egfl6 specific monoclonal antibodies and methods of their use
US11236153B2 (en) 2016-09-23 2022-02-01 Emory University Compositions and methods for identifying and sorting antigen-specific B cells
US20190284230A1 (en) * 2016-09-29 2019-09-19 Macfarlane Burnet Institute For Medical Research And Public Health Limited Assembled glycoproteins
CN109160942B (zh) * 2018-09-26 2021-06-29 广州市第八人民医院 Hcv包膜蛋白高度保守区域的肽段502-518及其用途
CN113125712B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种丙型肝炎病毒抗体的均相化学发光检测试剂盒及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2212511B (en) * 1987-11-18 1992-01-22 Chiron Corp Hepatitis c virus
KR0185373B1 (ko) * 1989-03-17 1999-05-01 로버트 피. 블랙버언 Hcv 폴리단백질에서 유래되는 hcv 아미노산 서열 부분을 포함하는 폴리펩티드 및 그 사용
KR100189050B1 (ko) * 1989-12-01 1999-06-01 펜스케 라피체 이온에 대한 착물 리간드를 함유하는 강유전성 액정 혼합물 및 액정 스위칭 또는 디스플레이 장치
US5308750A (en) * 1989-12-22 1994-05-03 Abbott Laboratories Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same
US5582968A (en) * 1990-02-16 1996-12-10 United Biomedical, Inc. Branched hybrid and cluster peptides effective in diagnosing and detecting non-A, non-B hepatitis
US5747239A (en) * 1990-02-16 1998-05-05 United Biomedical, Inc. Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines
ATE185486T1 (de) * 1990-06-29 1999-10-15 Chiron Corp Liposomen enthaltende impfstoffzusammensetzungen
EP0554241A1 (fr) * 1990-10-15 1993-08-11 LIPP, Robert Edmond Dispositif d'orientation des pales d'un rotor dans un flux transversal de fluide et application de celui-ci
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
SK286106B6 (sk) * 1990-11-08 2008-03-05 Novartis Vaccines & Diagnostics, Inc. Spôsob vykonávania imunodiagnostickej skúšky na detekciu protilátky proti vírusu hepatitídy C
AU662517B2 (en) 1991-01-31 1995-09-07 Abbott Laboratories Monoclonal antibodies to putative HCV envelope region and methods for using same
FR2677372B1 (fr) * 1991-06-06 1994-11-10 Pasteur Institut Sequences nucleotidiques et peptidiques d'un isolat de virus de l'hepatite c, applications diagnostiques et therapeutiques.
DE4209215A1 (de) * 1991-07-04 1993-01-07 Boehringer Mannheim Gmbh Hcv peptidantigene und verfahren zur bestimmung von hcv
AT397102B (de) * 1991-07-09 1994-02-25 Ahsen Uwe Von Dr Verwendung eines antibiotikums des typs 2-desoxystreptamin
IT1249684B (it) * 1991-07-19 1995-03-09 Sorin Biomedica Spa Epitopi della proteina env del virus dell'epatite c.
CA2115926A1 (en) * 1991-08-21 1993-03-04 Stephen H. Dailey Hepatitis c assay utilizing recombinant antigens to ns1
WO1993004888A1 (de) 1991-09-06 1993-03-18 Siemens Aktiengesellschaft Vorrichtung zur einhaltung einer vorgewählten fahrtrichtung eines fahrzeuges, insbesondere elektroautos, an steigungen
WO1993006126A1 (en) * 1991-09-13 1993-04-01 Chiron Corporation Immunoreactive hepatitis c virus polypeptide compositions
AU2683792A (en) * 1991-09-16 1993-04-27 Genelabs Technologies, Inc. Peptide based hepatitis c virus immunoassays
ATE191792T1 (de) * 1991-09-16 2000-04-15 Abbott Lab Verfahren zur detektion von hepatitis c
JP3158177B2 (ja) * 1991-10-08 2001-04-23 国立感染症研究所長 Ｃ型肝炎診断薬
CA2129733C (en) * 1992-01-31 2006-10-31 James M. Casey Mammalian expression systems for hcv proteins
US6165730A (en) * 1992-03-06 2000-12-26 N.V. Innogenetics S.A. Hepatitis C virus peptides obtained from the NS4 coding region and their use in diagnostic assays
US5866139A (en) * 1992-06-04 1999-02-02 Institut Pasteur Nucleotide and peptide sequences of a hepatitis C virus isolate, diagnostic and therapeutic applications
JPH05344899A (ja) 1992-06-11 1993-12-27 Kokuritsu Yobou Eisei Kenkyusho Ｃ型肝炎ウイルス外被タンパク質の産生法
UA39944C2 (uk) * 1992-07-07 2001-07-16 Чірон Корпорейшн Спосіб визначення ранньої сероконверсії у ссавця-хазяїна до вірусу гепатиту с і набір для використання в способі
US5514539A (en) * 1993-06-29 1996-05-07 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of the envelope 1 gene of 51 isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines
US5610009A (en) * 1994-01-28 1997-03-11 Abbott Laboratories Mammalian expression systems for hepatitis C virus envelope genes
SG71728A1 (en) 1994-07-29 2000-04-18 Innogenetics Nv Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
EP0947525A1 (en) * 1998-03-27 1999-10-06 Innogenetics N.V. Epitopes in viral envelope proteins and specific antibodies directed against these epitopes: use for detection of HCV viral antigen in host tissue

Also Published As

Publication number Publication date
DE69526636T4 (de) 2003-06-26
EP0721505B1 (en) 2002-05-08
WO1996004385A2 (en) 1996-02-15
US7026457B2 (en) 2006-04-11
JP2004222729A (ja) 2004-08-12
US20020182706A1 (en) 2002-12-05
SG71728A1 (en) 2000-04-18
US20030036110A1 (en) 2003-02-20
EP1211315A1 (en) 2002-06-05
JP4105203B2 (ja) 2008-06-25
EP0721505B2 (en) 2006-05-10
EP0721505A1 (en) 1996-07-17
PT721505E (pt) 2002-10-31
US6245503B1 (en) 2001-06-12
JP3892443B2 (ja) 2007-03-14
DK0721505T3 (da) 2002-08-19
US20080138894A1 (en) 2008-06-12
DE69526636T2 (de) 2002-12-12
ATE217345T1 (de) 2002-05-15
ES2174957T5 (es) 2006-12-16
DE69526636T3 (de) 2006-11-23
HK1049022A1 (zh) 2003-04-25
ES2174957T3 (es) 2002-11-16
JP2007105038A (ja) 2007-04-26
EP1845108A2 (en) 2007-10-17
JPH09503396A (ja) 1997-04-08
BR9506059A (pt) 1997-10-28
CA2172273A1 (en) 1996-02-15
WO1996004385A3 (en) 1996-03-07
US6890737B1 (en) 2005-05-10
EP1845108A3 (en) 2007-10-24
US20070128721A1 (en) 2007-06-07
DE69526636D1 (de) 2002-06-13
US6150134A (en) 2000-11-21

Similar Documents

Publication Publication Date Title
DK0721505T3 (da) Rensede hepatitis C-virus-kappeproteiner til diagnostisk og terapeutisk anvendelse
AU8700291A (en) Hcv-specific peptides, agents therefor and the use thereof
DK0591914T3 (da) Retrovirus fra HIV-gruppen og dets anvendelse
DK0992580T3 (da) Epitoper på human T-celler, som er immundominante for hepatitis C-virus
PT741515E (pt) Traducao transgenica de anticorpos no leite
DE69333673D1 (de) Epitope von Stress Proteinen
DE69735580D1 (de) An aminosaeure angereicherte speicherproteine, insbesondere an lysin angereicherte mais-gamma-zeine, und diese exprimierende pflanzen
ATE171216T1 (de) Expression und reinigung von rekombinantem, löslichem gewebefaktor
DK0523395T3 (da) Seroreaktive områder på proteinerne E1 og E2 i HPV 16
DE69434909D1 (de) Herstellung von humaninsulin
DK516485D0 (da) Fremgangsmaade til spaltning af peptider og proteiner ved methionyl-bindingen
MXPA04005891A (es) Proteinas envolventes del virus de hepatitis c purificadas para diagnostico y uso terapeutico.
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
CA2137280A1 (fr) Clonage du gene codant pour la proteine gp28.5 de toxoplasma gondii; fragments peptidiques de cette proteine et leurs applications
ES2062759T3 (es) Procedimiento de purificacion de polipeptidos recombinantes.
WO1994004675A3 (en) Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
WO1993017110A3 (en) A recombinant hepatitis c virus polypeptide
DE69832299D1 (de) Einkettigen polypeptiden enthalten troponin i und troponin c
WO2002055548A8 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
WO1991011513A3 (en) Catechol-o-methyltransferase, polypeptide sequences and dna molecule coding therefor